{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Taysha Gene Therapies, Inc.
Taysha Gene Therapies Hits Day Low at $3.97 Amid Price Pressure
Taysha Gene Therapies, Inc. has faced notable volatility, with a significant stock decline today. Despite a remarkable 191.5% return over the past year, the company has reported negative results for four consecutive quarters, raising concerns about its financial health and risk profile compared to historical valuations.
Taysha Gene Therapies Hits New 52-Week High at $5.51
Taysha Gene Therapies, Inc. has achieved a new 52-week high of USD 5.51, significantly up from its low of USD 1.05, reflecting a strong performance over the past year. The company, with a market cap of USD 884 million, operates in the competitive gene therapy sector despite ongoing losses.
Taysha Gene Therapies Hits Day High with 7.2% Surge in Stock Price
Taysha Gene Therapies, Inc. has seen significant gains, reaching an intraday high of USD 5.10, contrasting with a slight decline in the S&P 500. Despite impressive weekly and monthly performance, the company faces ongoing financial challenges, including negative results and cash flow issues over the past four quarters.
Taysha Gene Therapies Hits Day Low of $4.40 Amid Price Pressure
Taysha Gene Therapies, Inc. saw its stock decline significantly today, contrasting with a slight gain in the S&P 500. Despite a remarkable 119.9% growth over the past year, the company faces ongoing financial challenges, including negative results for four consecutive quarters and a substantial operating cash flow deficit.
Taysha Gene Therapies, Inc. Sees Revision in Stock Evaluation Amid Strong Market Performance
Taysha Gene Therapies, Inc. has recently revised its evaluation amid market fluctuations, with its stock currently priced at $4.42. Over the past year, it has seen a 52-week high of $5.40 and a low of $1.05, demonstrating notable performance compared to the S&P 500.
Is Taysha Gene Therapies, Inc. technically bullish or bearish?
As of October 3, 2025, Taysha Gene Therapies, Inc. shows a bullish technical trend with strong momentum indicators, despite a 78.31% decline over the past five years, while outperforming the S&P 500 year-to-date with a return of 155.49%.
Taysha Gene Therapies Hits New 52-Week High at $5.40
Taysha Gene Therapies, Inc. achieved a new 52-week high of USD 5.40 on October 3, 2025, reflecting a significant performance improvement from its previous low. With a market capitalization of USD 884 million, the company continues to navigate challenges in the biotechnology sector while outperforming the S&P 500.
Is Taysha Gene Therapies, Inc. technically bullish or bearish?
As of October 3, 2025, Taysha Gene Therapies, Inc. shows a bullish technical trend with strong buying pressure and significant outperformance against the S&P 500, despite some mixed indicator signals.
Taysha Gene Therapies, Inc. Experiences Revision in Stock Evaluation Amid Strong Performance
Taysha Gene Therapies, Inc. has recently revised its evaluation amid changing market conditions. The company has shown strong performance over the past year, significantly outperforming the S&P 500. Technical indicators present a mixed outlook, reflecting the company's resilience in the competitive biotechnology sector.
Is Taysha Gene Therapies, Inc. technically bullish or bearish?
As of September 19, 2025, Taysha Gene Therapies, Inc. shows a mildly bullish trend, supported by bullish daily moving averages and a mixed view from KST and Dow Theory, despite recent underperformance against the S&P 500.
Is Taysha Gene Therapies, Inc. technically bullish or bearish?
As of September 19, 2025, Taysha Gene Therapies, Inc. has a mildly bullish technical trend, supported by MACD, Bollinger Bands, and Dow Theory, despite a mildly bearish signal from KST, with a year-to-date return of 63.58% outperforming the S&P 500's 13.31%, but a short-term decline of -7.82% compared to the S&P 500's 1.22%.
Is Taysha Gene Therapies, Inc. technically bullish or bearish?
As of September 12, 2025, Taysha Gene Therapies, Inc. shows a mildly bullish trend, supported by positive indicators like the weekly MACD and Bollinger Bands, despite a recent decline and mixed signals from the KST.
Taysha Gene Therapies, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics
Taysha Gene Therapies, Inc. has experienced notable stock fluctuations, closing at $3.07 with a 52-week range of $1.05 to $3.40. The company has outperformed the S&P 500 year-to-date and over the past year, showcasing its resilience in the Pharmaceuticals and Biotechnology sector amid mixed technical indicators.
Is Taysha Gene Therapies, Inc. overvalued or undervalued?
As of March 28, 2023, Taysha Gene Therapies, Inc. is rated as "risky" and overvalued, with a Price to Book Value of 13.49, an EV to EBITDA of -8.12, a negative ROE of -149.22%, and a 1-year stock return of -15.88%, significantly underperforming the S&P 500's 10.26% return.
Is Taysha Gene Therapies, Inc. technically bullish or bearish?
As of June 18, 2025, Taysha Gene Therapies, Inc. shows a mildly bullish trend supported by positive weekly MACD and Bollinger Bands, though caution is advised due to a mildly bearish KST on the monthly chart.
What does Taysha Gene Therapies, Inc. do?
Taysha Gene Therapies, Inc. develops adeno-associated virus-based gene therapies for monogenic diseases of the central nervous system. As of March 2025, it has a market cap of $666.90 million, with net sales of $2 million and a net loss of $22 million.
How big is Taysha Gene Therapies, Inc.?
As of Jun 18, Taysha Gene Therapies, Inc. has a market capitalization of 666.90 million and reported net sales of 7.22 million, with a net loss of 86.77 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
